Abstract: Provided is a method for evaluating efficacy of, or resistance to, a c-Met targeting agent including measuring a level of a PDGF protein and/or a PDGF coding gene.

Abstract: A method of predicting an effect of a c-Met inhibitor and/or selecting a subject for application of a c-Met inhibitor using TFF1, a method of monitoring an effect of a c-Met inhibitor using TFF1, and a method of treating and/or preventing cancer including administering a c-Met inhibitor to the selected subject.

Abstract: An anti-c-Met/anti-Ang2 bispecific antibody including (a) an anti-c-Met antibody or antigen-binding fragment thereof and (b) an anti-Ang2 antibody or antigen-binding fragment thereof, a pharmaceutical composition including the anti-c-Met/anti-Ang2 bispecific antibody, and a method using the anti-c-Met/anti-Ang2 bispecific antibody.

Abstract: A method for prevention or treatment of a cancer, comprising co-administering (a) an anti-c-Met antibody or an antigen-binding fragment thereof, and (b) at least one of lapatinib, regorafenib, vemurafenib or a combination thereof, to a subject in need thereof, and a pharmaceutical composition comprising (a) an anti-c-Met antibody or an antigen-binding fragment thereof, and (b) at least one of lapatinib, regorafenib, vemurafenib, or a combination thereof are provided.

Abstract: A video encoding and decoding methods and apparatuses for performing the methods thereof are provided. The video encoding method includes: determining a region in a current image having a change in at least one of a scale and an angle with respect to a reference image; generating variation information representing a variation in at least one of the scale and the angle between the region in the current image and a reference region in the reference image corresponding to the region in the current image; and encoding residual information representing a difference between a predicted sample value from the reference image and a sample value of the current image based on the generated variation information.

Abstract: There are provided a fusion protein formed by coupling of anti-c-Met antibody and VEGF-binding fragment, a bispecific antibody comprising the fusion protein, a polynucleotide encoding the fusion protein, a transformant comprising the polynucleotide, a pharmaceutical composition comprising the bispecific antibody as an active ingredient, and a method for preparing the bispecific antibody which is targeted at c-Met and VEGF at the same time, with improved anticancer and anti-angiogenesis effects, comprising coupling an anti-c-Met antibody with a VEGF-binding fragment.

Abstract: A method for displaying an electronic program guide (EPG), which includes one or more pages divided into a plurality of program name display regions, provides a list of names of currently-broadcast programs through each of the program name display regions such that a user may search all currently-broadcast programs. TV viewers may determine information on currently-broadcast programs through an effective display method with classification criteria, and quickly change a page screen through movement between columns. TV viewers may select a desired broadcasting program from the channels through a minimum key manipulation of a remote control. Program names are classified according to the classification criteria such as genres, recently watched channels, and favorite channels in the EPG. The classification criteria may be set by each user, or a separate item may be added, so that a user may easily acquire broadcasting program information.

Abstract: A method of combination therapy for prevention and/or treatment of c-Met- and/or EGFR-induced diseases including co-administering a pharmaceutically effective amount of an EGFR antagonist and a pharmaceutically effective amount of an anti-c-Met antibody to a subject in need thereof is provided.

Abstract: A target substance used for combination treatment with an anti-c-Met antibody, a pharmaceutical composition for combination administration for preventing and/or treating cancer including an anti-c-Met antibody and an inhibitor against the target substance as active ingredients, a method for preventing and/or treating cancer including co-administering an anti-c-Met antibody and an inhibitor against the target substance, and a method for screening a drug for preventing and/or treating cancer using the target substance.

Abstract: A method for inhibiting angiogenesis and treating angiogenesis related diseases comprising administering an anti-c-Met antibody or an antigen-binding fragment thereof, and an anti-Ang-2 antibody or an antigen-binding fragment thereof, in combination simultaneously or sequentially; as well as related compositions and methods.

Abstract: There are provided a composition for determining the efficacy of a c-Met antibody including marker genes and a method for determining the efficacy of a c-Met antibody using the marker genes.

Abstract: A respiratory monitoring system includes: a first sensing tube provided in a respiratory flow tube and provided with at least a first directional hole opened in a respiratory flow direction; a second sensing tube provided with at least a second directional hole corresponding to the first directional hole; a first sensing element configured to detect a first dynamic pressure (PL) using a differential pressure between gas flows from the first and second sensing tubes; a second sensing element configured to detect a second dynamic pressure (PH) using a differential pressure between gas flows from the first and second sensing tubes; and a computation unit configured to compute patient's respiration information including a tidal inspiratory volume and a tidal expiratory volume using the first and second dynamic pressures.

Abstract: The disclosure is related to selecting and allocating one of resources in a cloud computing system to create a virtual machine. A control server may determine a resource selection reference by selecting one of fault-tolerance and network efficiency upon receipt of a request message for creating a target virtual machine. The control server may calculate at least one of a fault-tolerance point and a network efficiency point of each candidate resource according to the selected resource selection reference. The control server may select one of candidate resources to create a requested virtual machine based on at least one of the calculated fault-tolerance point and the calculated network efficiency point of the candidate resources.

Abstract: A method of preventing and/or treating a cancer including co-administering a c-Met inhibitor and a beta-catenin inhibitor to a subject in need thereof, a pharmaceutical composition comprising a c-Met inhibitor and a beta-catenin inhibitor, and a kit comprising a pharmaceutical composition comprising a c-Met inhibitor, and a pharmaceutical composition comprising a beta-catenin inhibitor packaged together.

Abstract: A method of preventing and/or treating a cancer including co-administering a c-Met inhibitor and a c-Myc Inhibitor to a subject in need thereof, a pharmaceutical composition comprising a c-Met inhibitor and a c-Myc inhibitor, and a kit comprising a pharmaceutically effective amount of a c-Met inhibitor as an active ingredient, and a second pharmaceutical composition comprising a pharmaceutically effective amount of a c-Myc inhibitor as an active ingredient, packaged together.

Abstract: A content program information search system and method is described. The system comprises a digital signal receiver for detecting and displaying a content signal and/or detailed content information for one or more search terms from a digital signal transmitted from a transmitter; and a server having a database for storing search terms inputted from external devices, the inputted search terms being stored by order of priority based for example on search frequency, such that the server extracts and transmits to the transmitter search terms from the first database, and the digital signal receiver displays according to the order of priority at least one search term transmitted from the transmitter. The viewer thus has search terms of high search frequency to enable the viewer to rapidly and easily search for information on a desired content program.

Abstract: An antibody or antigen binding fragment thereof that specifically binds to an epitope in a SEMA domain of c-Met protein, and pharmaceutical compositions, methods, kits, nucleic acids, and cells related thereto.

Abstract: A lancet holder includes a holder body having a lancet seat at one end to mount a lancet and receiving the lancet and elastic fixing portions arranged in pairs to face each other on the inner side of the holder body so that the lancet received in the holder body is vertically held, and elastically fixing the lancet.

Abstract: A method of preventing and/or treating a cancer, the method including co-administering a dual inhibitor of c-Met (hereinafter, ‘c-Met inhibitor’) and an IGF-1R inhibitor to a subject in need thereof and a use of IGF-1R as a marker for resistance to a c-Met inhibitor.

Abstract: A method of preventing and/or treating a cancer, the method including co-administering a dual inhibitor of c-Met and EGFR (hereinafter, ‘c-Met/EGFR dual inhibitor’) and an IGF-1R inhibitor to a subject in need thereof and a use of IGF-1R as a marker for resistance to a c-Met/EGFR dual inhibitor